224 related articles for article (PubMed ID: 32691140)
1. Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study.
Vantaggiato L; Perruzza M; Refini RM; Bergantini L; d'Alessandro M; Cameli P; Perruzza D; Bini L; Bargagli E; Landi C
Lung; 2020 Oct; 198(5):761-765. PubMed ID: 32691140
[TBL] [Abstract][Full Text] [Related]
2. Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab.
Landi C; Cameli P; Vantaggiato L; Bergantini L; d'Alessandro M; Perruzza M; Carleo A; Shaba E; Di Giuseppe F; Angelucci S; Bargagli E; Bini L
Biochim Biophys Acta Proteins Proteom; 2021 Feb; 1869(2):140563. PubMed ID: 33176218
[TBL] [Abstract][Full Text] [Related]
3. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
4. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
[TBL] [Abstract][Full Text] [Related]
6. Differential redox proteomic profiles of serum from severe asthma patients after one month of benralizumab and mepolizumab treatment.
Landi C; Vantaggiato L; Shaba E; Cameli P; Carleo A; d'Alessandro M; Bergantini L; Bargagli E; Bini L
Pulm Pharmacol Ther; 2021 Oct; 70():102060. PubMed ID: 34303823
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
[TBL] [Abstract][Full Text] [Related]
8. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
Hillas G; Fouka E; Papaioannou AI
Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
[No Abstract] [Full Text] [Related]
9. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
10. Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis.
Ramonell RP; Iftikhar IH
Lung; 2020 Feb; 198(1):95-103. PubMed ID: 31894410
[TBL] [Abstract][Full Text] [Related]
11. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study).
Martínez-Moragón E; García-Moguel I; Nuevo J; Resler G;
BMC Pulm Med; 2021 Dec; 21(1):417. PubMed ID: 34922515
[TBL] [Abstract][Full Text] [Related]
12. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
Pelaia C; Busceti MT; Solinas S; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
[TBL] [Abstract][Full Text] [Related]
13. Benralizumab (Fasenra) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2018 Feb; 60(1541):33-35. PubMed ID: 29485975
[No Abstract] [Full Text] [Related]
14. Reslizumab (Cinqair) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
[No Abstract] [Full Text] [Related]
15. Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study.
Isoyama S; Ishikawa N; Hamai K; Matsumura M; Kobayashi H; Nomura A; Ueno S; Tanimoto T; Maeda H; Iwamoto H; Hattori N
Intern Med; 2022; 61(11):1663-1671. PubMed ID: 35650114
[TBL] [Abstract][Full Text] [Related]
16. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma.
Pelaia C; Busceti MT; Crimi C; Carpagnano GE; Lombardo N; Terracciano R; Vatrella A; Pelaia G
Biomed Pharmacother; 2020 Sep; 129():110444. PubMed ID: 32593131
[TBL] [Abstract][Full Text] [Related]
17. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma].
Zyryanov SK; Avdeev SN; Ivanov DA; Zhuravleva MV; Kniajeskaia NP; Matveev NV; Nenasheva NA; Fomina DS; Frolov MI
Ter Arkh; 2020 Dec; 92(12):172-179. PubMed ID: 33720591
[TBL] [Abstract][Full Text] [Related]
19. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
[TBL] [Abstract][Full Text] [Related]
20. Role of eosinophilic chronic rhinosinusitis in switching to benralizumab treatment in mepolizumab responders.
Hamada S; Kobayashi Y; Yasuba H
Int J Clin Pharmacol Ther; 2020 Dec; 58(12):703-708. PubMed ID: 32831163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]